Abraham Morgentaler, MD, FACS, presented “Androgen Society 3rd Annual Meeting Review (Day 1)” for the Grand Rounds in Urology audience in May 2021.
How to cite: Morgentaler, Abraham. “Androgen Society 3rd Annual Meeting Review (Day 1)” May 2021. Accessed Jul 2022. https://dev.grandroundsinurology.com/androgen-society-3rd-annual-meeting-review-day-1/
Androgen Society 3rd Annual Meeting Review (Day 1) – Summary:
Abraham Morgentaler, MD, FACS, Associate Clinical Professor of Urologic Surgery at Harvard University, reviews the first day of the 3rd annual meeting of the Androgen Society, an international organization consisting of healthcare professionals interested in testosterone deficiency and its treatment. Dr. Morgentaler notes that the day began with a presentation on the history of testosterone by Dr. Nieschlag, followed by a presentation by Drs. Ethan D. Grober and Michael S. Irwig on transgender men and the physical impact of testosterone. Dr. Morgentaler then reviews a panel discussion that covered the use of free testosterone, erythrocytosis management, and the role of testosterone therapy and PDE5 inhibitors in men with erectile dysfunction and low testosterone. He goes on to summarize presentations by Drs. E. David Crawford and Omer Raheem which covered the use of androgen deprivation therapy (ADT) in local disease, biochemical failure, and advanced disease, as well as the sexual effects of testosterone. Dr. Crawford presented data showing that there is value in having a testosterone level below 20 nanograms per deciliter, and Dr. Raheem discussed a study that found that different forms of ADT should be used depending on patients’ cardiovascular issues. Dr. Morgentaler concludes by considering new testosterone formulations, including testosterone undecanoate, an oral soft gel, and injectables.
Summaries of days 2 and 3 of this conference will be posted on GRU in the coming weeks. For more on ADT, visit our Next Generation Androgen Deprivation Therapy Learning Center.